^
Association details:
| Biomarker: | FGFR2 fusion |
|---|---|
| Cancer: | Gastrointestinal Cancer |
| Drug: | derazantinib (ARQ 087) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Clinical Study to Evaluate Safety and Efficacy of ARQ 087 in Chinese Inoperable, Recurrent or Metastatic Intrahepatic Cholangiocarcinoma Subjects With Advanced Solid Tumors and FGFR2 Gene Fusion Positive Who Failed at Least First-Line Systemic Therapy
Excerpt:
...FGFR2 gene fusion confirmed with a central laboratory FISH testing (Applicable to Stage 2). ...
Trial ID:
Source:
Title:
A Phase 1/2 Study of ARQ 087 in Adult Subjects with Advanced Solid Tumors with FGFR Genetic Alterations Studio di fase I/II con ARQ 087 in soggetti adulti con Tumori solidi in stadio avanzato che presentino alterazione genetica FGFR
Excerpt:
...All subjects eligible for enrollment in the Expanded Cohort must have documented and/or confirmed FGFR genetic alterations, including iCCA with FGFR2 gene fusion. ...
Trial ID:
Less C2 evidence
Source:
Title:
The FGFR-inhibitor derazantinib (DZB) is active in PDX-models of GI-cancer with specific aberrations in FGFR.
Published date:
01/23/2020
Excerpt:
Known driver-mutations were associated with partial-responses (best dT/C = 0.42), but models with FGFR-fusions, especially FGFR2-fusions, were very sensitive leading to stasis or strong-regression, particularly in gastric cancer. High-expression of FGFR2 was also associated with strong responses….DZB showed convincing activity in GIC-models with FGFR-fusions and/or high expression.